- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Tildrakizumab – March 2026
Injection 100 mg in 1 mL single dose pre-filled syringe
Last updated
11 March 2026